Abstract
The metabolic syndrome (MetS) presents an increasing prevalence in elderly people. A significant role in MetS is played by the stress response and cortisol. The hypothalamic–pituitary–adrenal (HPA) axis activity is increased by central (loss of hippocampal glucocorticoid receptors) and peripheral (11β-hydroxysteroid dehydrogenase type 1, 11β-HSD1, hyperactivity) mechanisms. The HPA hyperactivity has been found in chronic diseases affecting the endocrine (abdominal obesity with MetS, type 2 diabetes), cardiovascular (atherosclerosis, essential hypertension), and nervous systems (dementia, depression), in aging. A novel therapeutic approach (11β-HSD1 inhibition) is promising in treating the HPA axis hyperactivity in chronic diseases with MetS. A large-scale national clinical trial (AGICO, AGIng, and COrtisol study) has been proposed by our group to evaluate the role of cortisol and MetS in the main pathologies of aging (vascular and degenerative dementia, cardiovascular diseases, type 2 diabetes, abdominal obesity).
Similar content being viewed by others
References
Third Report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). NIH Publication 2:1–284
Erkelens DW, de Bruin TWA, Cabezas MC (1993) Tulp syndrome. Lancet 342:1536–1537
Crepaldi G, Manzato E (1995) Polymetabolic syndrome. Minerva Endocrinol 20:155–160
Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of aWHO consultation. Diabet Med 15:539–553
Balkau B, Charles MA (1999) Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16:442–443
Third Report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421
Bloomgarden ZT (2003) American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome. Diabetes Care 26:1297–1303
Alberti KG, Zimmet P, Shaw J (2005) International Diabetes Federation (IDF) Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 366:1059–1062
Grundy SM, Cleeman JI, Daniels SR et al (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752
Alberti KGMM, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645
Seth SM, Abd TT, Jones SR et al (2014) ACC/AHA Cholesterol treatment guideline. What was done well and what could be done better. J Am Coll Cardiol 63:2674–2678
Cornier MA, Dabelea D, Hernandez TL et al (2008) The metabolic syndrome. End Rev 29:777–822
Maggi S, Noale M, Zambon A et al (2008) Validity of the ATP III diagnostic criteria for the metabolic syndrome in an elderly Italian Caucasian population: the Italian Longitudinal Study on Aging. Atherosclerosis 197:877–882
Stefanelli M, Martocchia A, De Marinis EA et al (2013) Prevalence of metabolic syndrome in cognitive impairment. Aging Clin Exp Res 25:351–352
Egger G, Dixon J (2010) Obesity prevention. Inflammatory effects of nutritional stimuli: further support for the need for a big picture approach to tackling obesity and chronic disease. Obes Rev 11:137–149
Fehevari Z (2012) Focus on the inflammasome. An inflammatory assemblage. Nat Immunol 13:320
Després JP, Lemieux I, Bergeron J et al (2008) Cardiometabolic risk abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 28:1039–1049
Bjorntorp P (1991) Visceral fat accumulation: the missing link between psychosocial factors and cardiovascular disease? J Intern Med 230:195–201
Björntorp P (2001) Do stress reactions cause abdominal obesity and comorbidities? Obes Rev 2:73–86
Martocchia A, Curto M, Toussan L et al (2011) Pharmacological strategies against glucocorticoid-mediated brain damage during chronic disorders. Rec Patents CNS Drug Discov 6:196–204
Falaschi P, Martocchia A, Proietti A et al (1994) Immune system and the hypothalamus pituitary–adrenal axis. Common words for a single language. Ann N Y Acad Sci 29:89–111
McEwen BS, Gianaros PJ (2010) Central role of the brain in stress and adaptation: links to socioeconomic status, health, and disease. Ann N Y Acad Sci 1186:190–222
Charmandari E, Tsigos C, Chrousos G (2005) Endocrinology of the stress response. Annu Rev Physiol 67:259–284
Herman JP, Ostrander MM, Mueller NK et al (2005) Limbic system mechanisms of stress regulation: hypothalamo-pituitary adrenocortical axis. Prog Neuropsychopharmacol Biol Psychiatry 29:1201–1213
Peiffer A, Barden N, Meaney MJ (1991) Age-related changes in glucocorticoid receptor binding and mRNA levels in the rat brain and pituitary. Neurobiol Aging 12:475–479
Sapolsky RM, Krey LC, McEwen BS (1983) The adrenocortical stress-response in the aged male rat: impairment of recovery from stress. Exp Gerontol 18:55–64
Van Cauter E, Leproult R, Kupfer DJ (1996) Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. J Clin Endocr Metab 81:2468–2473
Falaschi P (1993) Neuroendocrinoimmunology. 94° Congr SIMI Ed Luigi Pozzi, Rome, pp 315–416
Tomlinson JW, Stewart PM (2004) “Cushing’s disease of the omentum”—fact or fiction? J Endocrinol Invest 27:171–174
Duclos M, Marquez Pereira P, Barat P et al (2005) Increased cortisol bioavailability, abdominal obesity, and the metabolic syndrome in obese women. Obes Res 13:1157–1166
Seeman TE, McEwen BS, Rowe JW et al (2001) Allostatic load as a marker of cumulative biological risk: MacArthur studies of successful aging. Proc Natl Acad Sci 98:4770–4775
Meco G, Formisano R, Falaschi P et al (1985) Dexamethasone non-suppressor Parkinsonian patients: a subgroup with depression and mental impairment. In: Burrows GD, Norman TR, Dennerstein L (eds) Clinical and pharmacological studies in psychiatric disorders. John Lippey, London, pp 171–185
Dekker MJ, Koper JW, Van Aken MO et al (2008) Salivary cortisol is related to atherosclerosis of carotid arteries. J Clin Endocrinol Metab 93:3741–3747
Chiodini I (2011) Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab 96:1223–1236
Wirtz PH, Von Känel R, Emini L et al (2007) Evidence for altered hypothalamus–pituitary–adrenal axis functioning in systemic hypertension: blunted cortisol response to awakening and lower negative feedback sensitivity. Psychoneuroendocrinology 32:430–436
Gruenewald TL, Seeman TE, Karlamangla AS et al (2009) Allostatic load and frailty in older adults. J Am Geriatr Soc 57:1525–1531
Solfrizzi V, Scafato E, Frisardi V et al (2012) Frailty syndrome and all-cause mortality in demented patients: the Italian Longitudinal Study on Aging. Age (Dordr) 34:507–517
Waters DL, Qualls CR, Dorin RI et al (2008) Altered growth hormone, cortisol, and leptin secretion in healthy elderly persons with sarcopenia and mixed body composition phenotypes. J Gerontol A Biol Sci 63:536–541
Scafato E, Gandin C, Galluzzo L et al (2010) Prevalence of aging-associated cognitive decline in an Italian elderly population: results from cross-sectional phase of Italian PRoject on Epidemiology of Alzheimer’s disease (IPREA). Aging Clin Exp Res 22:440–449
Huang CW, Lui CC, Chang WN et al (2009) Elevated basal cortisol level predicts lower hippocampal volume and cognitive decline in Alzheimer’s disease. J Clin Neurosci 16:1283–1286
Raffaitin C, Tzourio C, Gin E et al (2009) Metabolic syndrome and risk for incident Alzheimer disease or vascular dementia: the three-city study. Diabetes Care 32:169–174
Vanhanen M, Koivisto K, Moilanen L et al (2006) Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 67:843–847
Stefanelli M, Martocchia A, De Marinis EA et al (2014) Treatment of insulin resistance in the neurodegeneration. Recent Patents CNS Drug Discovery 9:54–63
Murakami H, Nigawara T, Sakihara S et al (2010) The frequency of type 2 diabetic patients who meet the endocrinological screening criteria of subclinical Cushing’s disease. Endocr J 57:267–272
Hamer M, O’Donnell K, Lahiri A et al (2010) Salivary cortisol responses to mental stress are associated with coronary artery calcification in healthy men and women. Eur Heart J 31:424–429
Dennison E, Hindmarsh P, Fall C et al (1999) Profiles of endogenous circulating cortisol and bone mineral density in healthy elderly men. J Clin Endocrinol Metab 84:3058–3063
Maggi S, Siviero P, Gonnelli S et al (2011) The burden of previous fractures in hip fracture patients. The Break Study. Aging Clin Exp Res 23:183–186
Zillikens MC, Uitterlinden AG, Van Leeuwen JP et al (2010) The role of body mass index, insulin, and adiponectin in the relation between fat distribution and bone mineral density. Calcif Tissue Int 86:116–125
Doherty TM, Asotra K, Fitzpatrick LA et al (2003) Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci USA 100:11201–11206
Helas S, Goettsch C, Schoppet M et al (2009) Inhibition of receptor activator of NF-kappa B ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol 175:473–478
Martocchia A, Toussan L, Stefanelli M et al (2011) Association of severity of osteoarthritis and carotid atherosclerosis in patients with metabolic syndrome. Rheumatol Open Access J 1:1–3
Stewart PM, Krozowski ZS (1999) 11β-Hydroxysteroid dehydrogenase. Vitam Horm 57:249–324
Basu R, Singh RJ, Basu A et al (2004) Splanchnic cortisol production occurs in humans evidence for conversion of cortisone to cortisol via the 11-β hydroxysteroid dehydrogenase (11β-HSD) type 1 pathway. Diabetes 53:2051–2059
Moisan MP, Seckl JR, Edwards CR (1990) 11β-Hydroxysteroid dehydrogenase bioactivity and messenger RNA expression in rat forebrain: localization in hypothalamus, hippocampus, and cortex. Endocrinology 127:1450–1455
Veilleux A, Rhéaume C, Daris M et al (2009) Omental adipose tissue type 1 11beta-hydroxysteroid dehydrogenase oxoreductase activity, body fat distribution, and metabolic alterations in women. J Clin Endocrinol Metab 94:3550–3557
Wake DJ, Rask E, Livingstone DE et al (2003) Local and systemic impact of transcriptional up-regulation of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J Clin Endocrinol Metab 88:3983–3988
Cooper MS, Rabbitt EH, Goddard PE et al (2002) Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res 17:979–986
Morton NM, Paterson JM, Masuzaki H et al (2004) Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53:931–938
Martocchia A, Stefanelli M, Falaschi GM et al (2013) Targets of anti-glucocorticoid therapy for stress-related disease. Recent Patents CNS Drug Discov 8:79–87
Alberts P, Engblom L, Edling N et al (2002) Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 45:1528–1532
Hermanowski-Vosatka A, Balkovec JM, Cheng K et al (2005) 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 202:517–527
Rosenstock J, Bananer S, Fonseca VA et al (2010) The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled Bb metformin monotherapy. Diabetes Care 33:1516–1522
Feig PU, Shah S, Hermanowski-Vosatka A et al (2011) Effects of an 11-betahydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab 13:498–504
Shah S, Hermanowski-Vosatka A, Gibson K et al (2011) Efficacy and safety of the selective 11β-HSD1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. J Am Soc Hypertension 5:166–176
Conflict of interest
None.
Human and Animal Rights
The article does not contain any studies with human participants or animals performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Martocchia, A., Stefanelli, M., Falaschi, G.M. et al. Recent advances in the role of cortisol and metabolic syndrome in age-related degenerative diseases. Aging Clin Exp Res 28, 17–23 (2016). https://doi.org/10.1007/s40520-015-0353-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40520-015-0353-0